Cofounder, @LeashBio.

Salt Lake City, UT
Ian Quigley retweeted
Today we can finally talk about @enveda's partnership with @AnthropicAI . “Partnership” is a word that covers a lot of sins, so here is what it actually bought us: 1. a Phase 2 program pulled forward by three weeks 2. an IND submission accelerated for another soon-to-be-announced clinical program 3. an Investigator’s Brochure, drafted by @claudeai and signed off by our team after one minor edit, now in front of the FDA We chose to work with Anthropic on development, not discovery. Enveda already finds medicines faster than we can develop them, and I think the industry is heading the same way. The slowest part of development is paperwork, directly or indirectly: batch records, study reports, the Investigator’s Brochure, and the IND that packages it all for the FDA. Discovery gets the headlines. Document review is where the months go. Test 1: manufacturing batch release for a Phase 2 program. Before a batch can go to a trial, someone checks every page of its manufacturing record by hand. Claude read 1,061 scanned, largely handwritten pages from the campaign. Four of our reviewers and outside consultants independently reviewed the same pages, and a Quality adjudicator scored every comment against one question: would an FDA auditor raise it? Claude matched all 11 actionable issues the experts found and added 7 they had missed. Review time fell from 26 hours (typically spread over several weeks) to under 3, an 89% reduction, for about $37 in model cost. On another program, it flagged a climbing impurity that routine review had cleared; it later went out of specification. Test 2: the Investigator’s Brochure for an IND, drafted in four hours instead of weeks. For a new Enveda medicine about to enter human trials, Claude drafted the brochure every trial physician relies on, from a structured layer of facts pulled from our tox, bioanalytical, and PK reports. Our reviewers found one minor unit-conversion error. We fixed it and included that draft in the IND. From the same source layer, Claude drafted the core of the IND itself in four hours, work that takes the best teams a month or more. None of this works unless the model stays factful, so we built a custom harness to force it. It reads every page as an image, keeps a code ledger of which pages it read, and ties every finding to its page and governing document. Across the evaluation, no finding cited anything that was not in the record. The full method is public. Our technical report on the CMC Document Processor covers the architecture, GMP controls, study design, and results, and we open-sourced a companion implementation so you can build your own! Thank you to the incredible @enveda and @AnthropicAI teams for making this possible.
Patients cannot wait another day for tomorrow’s medicines. Today, bringing a drug to market can take more than 10 years and cost over $1 billion. A major contributor is the time and expense required to generate and review the documentation that helps to build medicines that are safe and effective. That is why we are thrilled to partner with @AnthropicAI to transform drug development, starting with our clinical-stage programs. Together, we built tools to address two major early-stage bottlenecks: preparing a complete IND package and reviewing CMC batch records for release. The results have been groundbreaking in speed, cost, and quality. Read more: anthropic.com/research/early…
7
11
86
6,238
Ian Quigley retweeted
By far the coolest part of the Texas Election Code is the chapter allowing astronauts, many of whom live around Houston, to vote from space. 🚀🌕👨‍🚀
13
141
1,014
48,557
Ian Quigley retweeted
“wet lab biologists are anti AI” I am like 100% scheduling my daily life around astra usage limits
12
10
349
11,584
Lots of talk on simulating biology over the weekend. I want to bring up this paper from 2012 to give a sense of what that might actually look like. Take a look at those different things we'd need to model. We have scalable measurements for maybe 5 of these.
5
19
110
4,777
Of course, these are cells by themselves. Not even gonna get into what this might take inside a tissue!
8
344
Thanks to @latentspacepod for this quickie episode! I talk about our physically grounded sandboxes, where agents can run their own experiments, and how they can help us understand model behavior. piped.video/watch?v=vhPCo-8K…
1
1
6
1,260
if you have a qwen3.5 4b around, please try steering neurons L14 N8949 +1 and L13 N7956 -1 now you have evil qwen recipe: dose × median(‖resid‖ leaving layer L, tokens 1:) / ‖W_down[:, n]‖` at the down_proj at every input
4
253
We have been studying freshwater eels for centuries, and we still don't really know where they spawn. You can have super-smart models and they'll still never know. You have to go out into the world and run experiments!
There’s a really pronounced divide between people who are on the AI side of things and people who are on the biology side of things. Even among people working in AI, the divide persists based on where they’re focused. The AI side, adherents of scaling laws and the bitter lesson, believe that AI getting better means AI being more capable of novel discoveries in medicine (that go beyond discovering new drugs in well understood targets or speeding up dry lab work etc). The biology people think the idea of a bitter lesson in biology is kind of ridiculous and that regardless of AI’s capabilities it’s going to be at least 5-10 years until you could hope to reliably simulate human toxicology in silico (right now AI/ML can’t even reliably simulate in vivo studies like binding affinities or functional assays). Even the most AI pilled of them, who will list all the areas that AI can reduce the time spent on various areas, don’t think the concept of AI discovering novel targets or generating new understanding of causal biology is realistic in the near term. Most, in fact, will readily characterize the assumption that even an “ASI” level model could find cures hidden in our current understanding (without expanding that understanding with significantly more biological data) as patently false. This was a big part of why we wanted to experience it ourselves by using AI for a (very) small portion of what it can do in biology. It was both mind blowing and revealed some poignant insights into how different the problem of making AI better at something like coding is to the problems of biology. Even if it unlocked the ability to generate new molecules at a stunning pace, its simulation (in silico) of binding only had 49% accuracy. And if we wanted to improve that, we’d need to feed it back the data from the lab - data that took about 30x as long to get as it took to generate the molecules. And these were tests in a test tube (turn of phrase), imagine how long it would take if we wanted to improve the model with data that required recruiting humans and monitoring their reactions. Human biology is very complex, and adding a drug - especially a novel drug and doubly so for a novel drug acting on a novel mechanism - means mapping interactions that have nth-order-effects that we don’t have the data to predict. Virtual cells have made advancements enabled by AI, but the perturbations equate to a small fraction of the possible. This is before you even get into curing disease, especially uniquely human diseases. Brain function involves cellular identities that are unique to humans, meaning animal studies are of little use. How long does it take to understand what the side effects of chronic administration of a drug in humans are? AI can speed up analyzing the data, or designing the trial or even getting it approved…but it can’t make a 6 month trial complete in 3 months. I think its important to point out that significant advancements can be made in AI that contribute to biology, while also being realistic about how much it speeds up something as complex as curing a specific cancer or diseases of the brain.
6
2
60
965
The most scalable data capture modalities in town are imaging and sequencing. With both of those modalities, you can capture maybe 60% of biology. carpenter-singh-lab.broadins… Time to invent new measurement methods!
1
1
114
Soviet scientists retrieve Strelka and Belka, the first living creatures to orbit the earth, from their capsule after safely returning from their mission, 1960.
12
105
1,100
20,040
Ian Quigley retweeted
Fall on the Wasatch Front
4
3
40
1,432
Ian Quigley retweeted
Maybe controversial: the conversation about scientific bottlenecks is overfocused on automation. New measurement technologies deserve more attention. You could automate an assay that needs an entire facility – or you could REINVENT the assay so that it fits into just a few tubes.
18
74
422
54,408
Ian Quigley retweeted
Labs in the loop - at compute speed. The future is on the cluster.
We premeasured physical worlds of millions of chemicals binding to proteins and let agents explore them. Here's what it looks like! 1/
1
1
15
1,249
We premeasured physical worlds of millions of chemicals binding to proteins and let agents explore them. Here's what it looks like! 1/
2
2
21
2,628
You don't have to believe me! We released a pile of these worlds at strelka.leash.bio/ for you to try this yourself. We also dropped thousands of transcripts there. Please check out our preprint at github.com/Leash-Labs/minos-… 7/
1
3
98
We think labs-in-the-loop will truly enable agentic science, which is why we built so many that they can explore at compute speed! /fin
1
87